bcl-2 and apoptosis in lymph node positive breast carcinoma

Area of Science:

• Oncology
• Molecular Biology

Background:

• Bcl-2 protein can inhibit apoptosis in vitro.
• Reduced apoptosis may correlate with increased malignant cell accumulation and aggressive disease.

Purpose of the Study:

• To investigate the prognostic significance of bcl-2 expression and apoptosis in breast carcinoma patients.
• To test the hypothesis that high bcl-2 and low apoptosis predict a worse prognosis.

Main Methods:

• Immunohistochemistry (IHC) was used to evaluate bcl-2 protein expression in 979 primary breast tumors.
• Apoptosis was assessed by detecting 3' DNA fragments using IHC.
• Analysis correlated findings with patient characteristics, prognostic factors, and clinical outcomes over a median follow-up of 61 months.

Main Results:

• High bcl-2 expression correlated with favorable prognostic factors: fewer positive lymph nodes, absence of p53, ER/PR positivity, diploidy, and lower proliferation rate.
• High bcl-2 expression was independently associated with significantly improved disease-free survival (DFS) and overall survival (OS).
• Increased apoptosis (> or = 1%) was linked to adverse factors (more positive lymph nodes, p53, ER/PR negativity, aneuploidy, higher proliferation) but not significantly to worse clinical outcomes.

Conclusions:

• In lymph node-positive breast cancer, high bcl-2 expression is a favorable prognostic indicator, independently predicting better outcomes.
• While apoptosis correlates with poor prognostic factors, it was not significantly associated with a worse clinical outcome in this patient cohort.